<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Xenetic Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/xenetic-biosciences-inc</link>
<description>Latest news and press releases for Xenetic Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/xenetic-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835db1f78dffbe2df123bda.webp</url>
<title>Xenetic Biosciences Inc</title>
<link>https://6ix.com/company/xenetic-biosciences-inc</link>
</image>
<item>
<title>Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting-2</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting-2</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-full-year-2025-financial-results-142</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-full-year-2025-financial-results-142</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-adjournment-220000964</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-adjournment-220000964</guid>
<pubDate>Thu, 11 Dec 2025 22:00:00 GMT</pubDate>
<description>Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-extends-research-134500955</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-extends-research-134500955</guid>
<pubDate>Wed, 19 Nov 2025 13:45:00 GMT</pubDate>
<description>FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-third-134500156</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-third-134500156</guid>
<pubDate>Thu, 13 Nov 2025 13:45:00 GMT</pubDate>
<description>Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS Newswire / November 13, 2025 /Xenetic ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-pricing-133000148</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-pricing-133000148</guid>
<pubDate>Fri, 10 Oct 2025 13:30:00 GMT</pubDate>
<description>FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-second-120000812</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-second-120000812</guid>
<pubDate>Wed, 13 Aug 2025 12:00:00 GMT</pubDate>
<description>Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies Ended the quarter with $4.8 million of cash to fund operations ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-entry-130000831</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-entry-130000831</guid>
<pubDate>Wed, 30 Jul 2025 13:00:00 GMT</pubDate>
<description>Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-expands-research-123000301</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-expands-research-123000301</guid>
<pubDate>Wed, 23 Jul 2025 12:30:00 GMT</pubDate>
<description>Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-collaboration-130000506</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-collaboration-130000506</guid>
<pubDate>Tue, 08 Jul 2025 13:00:00 GMT</pubDate>
<description>Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess Company evaluating systemic recombinant human DNase I (DNase I) in combination with chemotherapy and immunotherapy ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreat...</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-update-from-collaboration-partner-of-first-patient-dosed-in-exploratory-clinical-study-of-dnase-i-in-combination-with-folfirinox-for-the-first-line-treatment-of-unresectable-locally-advanced-or-metastatic-pancreat</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-update-from-collaboration-partner-of-first-patient-dosed-in-exploratory-clinical-study-of-dnase-i-in-combination-with-folfirinox-for-the-first-line-treatment-of-unresectable-locally-advanced-or-metastatic-pancreat</guid>
<pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
<description>Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-first-120500544</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-first-120500544</guid>
<pubDate>Wed, 14 May 2025 12:05:00 GMT</pubDate>
<description>Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma Ended the quarter with ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-releases-virtual-131500464</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-releases-virtual-131500464</guid>
<pubDate>Wed, 09 Apr 2025 13:15:00 GMT</pubDate>
<description>- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment </title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-releases-virtual-investor-what-this-means-segment</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-releases-virtual-investor-what-this-means-segment</guid>
<pubDate>Wed, 09 Apr 2025 04:00:00 GMT</pubDate>
<description>- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-entry-130000705</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-entry-130000705</guid>
<pubDate>Wed, 26 Mar 2025 13:00:00 GMT</pubDate>
<description>Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma </title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-entry-by-collaboration-partner-into-a-clinical-study-agreement-to-advance-development-of-dnase-platform-for-the-treatment-of-relapsedrefractory-osteosarcoma-and-ewing-sarcoma</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-announces-entry-by-collaboration-partner-into-a-clinical-study-agreement-to-advance-development-of-dnase-platform-for-the-treatment-of-relapsedrefractory-osteosarcoma-and-ewing-sarcoma</guid>
<pubDate>Wed, 26 Mar 2025 04:00:00 GMT</pubDate>
<description>Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire /</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-full-120500549</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-full-120500549</guid>
<pubDate>Wed, 19 Mar 2025 12:05:00 GMT</pubDate>
<description>Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results </title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-full-year-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-reports-full-year-2024-financial-results</guid>
<pubDate>Wed, 19 Mar 2025 04:00:00 GMT</pubDate>
<description>Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus on</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses</title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-presents-positive-123000628</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-presents-positive-123000628</guid>
<pubDate>Thu, 13 Mar 2025 12:30:00 GMT</pubDate>
<description>Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but ...</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses </title>
<link>https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-presents-positive-preclinical-data-underscoring-the-potential-of-dnase-i-as-an-adjunctive-treatment-to-enhance-immunotherapeutic-responses</link>
<guid isPermaLink="true">https://6ix.com/company/xenetic-biosciences-inc/news/xenetic-biosciences-inc-presents-positive-preclinical-data-underscoring-the-potential-of-dnase-i-as-an-adjunctive-treatment-to-enhance-immunotherapeutic-responses</guid>
<pubDate>Thu, 13 Mar 2025 04:00:00 GMT</pubDate>
<description>Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFindings demonstrate that by degrading neutrophil</description>
</item>
</channel>
</rss>